In attempts to explain this finding, neurodegenerative biomarkers like neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were measured and found to be higher in COVID-19 patients than non-COVID-19 patients with mild cognitive impairment or AD [71]. The gene discussed is NEFL; the disease is COVID-19.